Literature DB >> 32488115

Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia.

Rishi S Kotecha1,2,3, Ronald W Stam4, Priscilla Wander5,6, Laurence C Cheung7,8, Sandra S Pinhanҫos5,9, Luke Jones5, Mark Kerstjens6, Susan T C J M Arentsen-Peters5, Sajla Singh7, Grace-Alyssa Chua7, Patricia Garrido Castro5, Pauline Schneider5, M Emmy M Dolman5, Bianca Koopmans5, Jan J Molenaar5, Rob Pieters5, C Michel Zwaan5,6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32488115     DOI： 10.1038/s41375-020-0895-9

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  2 in total

1.  Fludarabine-mediated inhibition of nucleotide excision repair induces apoptosis in quiescent human lymphocytes.

Authors:  A Sandoval; U Consoli; W Plunkett
Journal:  Clin Cancer Res       Date:  1996-10       Impact factor: 12.531

2.  Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine.

Authors:  V Heinemann; L W Hertel; G B Grindey; W Plunkett
Journal:  Cancer Res       Date:  1988-07-15       Impact factor: 12.701
  2 in total
  3 in total

1.  Preclinical efficacy of prexasertib in acute lymphoblastic leukemia.

Authors:  Jason Ostergaard; Leslie M Jonart; Maryam Ebadi; Stacia L Koppenhafer; David J Gordon; Peter M Gordon
Journal:  Br J Haematol       Date:  2021-06-07       Impact factor: 6.998

2.  Systematic In Vitro Evaluation of a Library of Approved and Pharmacologically Active Compounds for the Identification of Novel Candidate Drugs for KMT2A-Rearranged Leukemia.

Authors:  Mawar Karsa; Emma Ronca; Angelika Bongers; Anna Mariana; Ernest Moles; Timothy W Failes; Greg M Arndt; Laurence C Cheung; Rishi S Kotecha; Maria Kavallaris; Michelle Haber; Murray D Norris; Michelle J Henderson; Lin Xiao; Klaartje Somers
Journal:  Front Oncol       Date:  2022-01-20       Impact factor: 6.244

3.  Molecular Characterization of the Response to Conventional Chemotherapeutics in Pro-B-ALL Cell Lines in Terms of Tumor Relapse.

Authors:  Yvonne Saara Gladbach; Lisa-Madeleine Sklarz; Catrin Roolf; Julia Beck; Ekkehard Schütz; Georg Fuellen; Christian Junghanss; Hugo Murua Escobar; Mohamed Hamed
Journal:  Genes (Basel)       Date:  2022-07-14       Impact factor: 4.141
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.